BioSpace News Archive

Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that members of the Syndax management team will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 8:00 a.m. PT/ 11:00 a.m. ET.

Amylyx Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2024.

Xeris Biopharma Holdings, Inc. announced financial results for the first quarter ended March 31, 2024 and recent events.

Orthofix Medical Inc., a leading global spine and orthopedics company, announced that it has received U.S. Food and Drug Administration 510 clearance to market its Rodeo™ Telescopic Nail. This press release features multimedia.

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced its first quarter 2024 results and provided a business update.

Nxera Pharma provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2024.

Freeline Therapeutics announced new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus gene therapy candidate for Gaucher disease, showing substantial reductions in glucosylsphinogsine, one of the best predictors of clinical response, in patients with persistently high levels despite years of treatment with currently approved therapies, as well as early signs of clinical improvements in bone marrow burden and fatigue.

Theravance Biopharma, Inc. will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Monday, May 20 at 11:30 AM EDT and will be hosting in-person meetings with the investment community at the conference.

Merakris Therapeutics announced that Jonathan Berlent has joined the company as Senior Vice President, Head of Strategy and Operations.

Monopar Therapeutics Inc., a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, announced first quarter 2024 financial results and summarized recent developments.